SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapy—evidence and implications

被引：0
|
作者：
Anil Pareek
Ravi T. Mehta
Shruti Dharmadhikari
机构：
[1] Ipca Laboratories Limited,Medical Affairs and Clinical Research Department
来源：
International Journal of Diabetes in Developing Countries | 2020年 / 40卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：636 / 637
页数：1
相关论文
共 50 条
  • [1] SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapy-evidence and implications
    Pareek, Anil
    Mehta, Ravi T.
    Dharmadhikari, Shruti
    [J]. INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2020, 40 (04) : 636 - 637
  • [2] SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?
    Cervantes, Carlos Escobar
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (08): : 507 - 508
  • [3] GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
    Nauck, Michael A.
    Meier, Juris J.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (12): : 963 - 964
  • [4] SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
    De Block, Christophe
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05): : 349 - 352
  • [5] Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor
    DeFronzo, Ralph A.
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1353 - 1362
  • [6] SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
    Brown, Emily
    Heerspink, Hiddo J. L.
    Cuthbertson, Daniel J.
    Wilding, John P. H.
    [J]. LANCET, 2021, 398 (10296): : 262 - 276
  • [7] Effect of an SGLT2 Inhibitor in Japanese Type 2 Diabetic Patients Receiving GLP-1 Receptor Agonists
    Onishi, Tetsuro
    Taniguchi, Yukiko
    Mori, Yutaka
    [J]. DIABETES, 2017, 66 : A324 - A324
  • [8] SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
    Scheen, Andre J.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11): : 818 - 820
  • [9] Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1566): : 26 - 28
  • [10] Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer, Milton
    [J]. AMERICAN JOURNAL OF MEDICINE, 2018, 131 (05): : 461 - 463
12345